Skip to main
ACLX
ACLX logo

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 62%
Buy 31%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. demonstrates a robust growth trajectory, with Carvykti sales averaging a 32% quarter-over-quarter increase over the past three years, indicating strong market demand. The expanding access to community physicians capable of administering CAR T therapies has risen significantly from 29% to 47% within the same timeframe, underscoring the increasing acceptance and implementation of innovative treatments. Furthermore, strong clinical data from Phase 1 and Phase 2 trials for anito-cel, combined with potential market dominance projected to achieve $4.7 billion in sales by 2035, enhances the company's growth prospects in a rapidly expanding CAR T market.

Bears say

Arcellx Inc. faces a negative outlook primarily due to its sales estimates for anti-cel, which fall short of consensus projections for the overall CAR T market in multiple myeloma, with 2035 sales estimated at $11.5 billion compared to $16.5 billion. The company also grapples with significant risks, including the potential for unsuccessful drug pipeline execution, ongoing drug pricing control discussions in Washington, D.C., and adverse conditions in biotechnology capital markets. Additionally, despite promising clinical data, barriers to community adoption of CAR T therapies suggest a challenging path forward, further complicating the company’s revenue prospects.

Arcellx (ACLX) has been analyzed by 13 analysts, with a consensus rating of Buy. 62% of analysts recommend a Strong Buy, 31% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Buy based on their latest research and market trends.

According to 13 analysts, Arcellx (ACLX) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.